

November 08, 2023

The Manager (Listing)
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort
Mumbai 400001

Dear Sir/Madam,

Ref. Scrip code: 539680

Sub.: Outcome of the Board Meeting pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 held on Wednesday, November 08, 2023

Dear Sir/Madam,

With reference to the captioned subject and in compliance with the Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, this is to inform you that the Board of Directors of the Company at its Meeting held today i.e., on November 08, 2023 inter-alia have considered and approved the Un-audited financial results of the Company for the half year ended on September 30, 2023.

A copy of the Un-audited Financial Results adopted and approved by the Board of Directors for the half year ended on September 30, 2023 along with limited review report of the Auditors thereon is attached herewith.

The Meeting was commenced at 11.30 a.m. and concluded at 12.05 p.m.

Please take the same on your records and suitably disseminated at all concerned.

Thanking you,

Yours faithfully,
For Ganga Pharmaceuticals Limited

SHARMA
B
BHARAT B
Digitally signed by
SHARMA BHARAT
B
Date: 2023.11.08
12:10:02 +05'30'

Bharat Sharma
Managing Director
DIN No: 00077026
Email ID: bharat.sharma@gangapharma.in

Encl. As above



Independent Auditors' Review Report on the Standalone half yearly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF GANGA PHARMACEUTICALS LIMITED

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Ganga Pharmaceuticals Limited ("the company") for the half year ended September 30, 2023 ("the statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountant of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Yours Faithfully,

For BANKA & BANKA

CHARTERED ACCOUNTANTS

ICAI FIRM REG. NO. : 100979W



Pradeep P. Banka

(Pradeep P. Banka)

PARTNER

Membership No.038800

UDIN: 23038800BGVOQH8528

Mumbai:- 08.11.2023

GANGA PHARMACEUTICALS LIMITED

CIN: L99999MH1989PLC053392

REGISTERED OFFICE ADDRESS : GANGATAT, DHANVANTARI MARG, GOPCHAR PADA, VIRAR (EAST)-401 305.

Tele No.+91-250-6098444 Email id: gangapharmaltd@gmail.com, Website: www.ayurvedganga.com

Statement of Un-Audited Financial Results for the Half and Year ended 30 September,2023.

Rs.in Lacs

Sr. No	Particulars	Figures for the half year ended on			Financial year ended on	Financial year ended on
		30-09-2023	31-03-2023	30-09-2022	31-03-2023	31-03-2022
		(Un-Audited)	(Audited)	(Un-Audited)	(Audited)	(Audited)
1	INCOME FROM OPERATIONS					
	(a) Revenue from operations	131.93	123.48	135.16	258.63	248.90
	(b) Other Income	8.88	17.78	12.04	29.82	25.86
	Total Income	140.82	141.26	147.19	288.45	274.76
2	Expenses:					
	(a) Cost of Materials consumed	63.21	72.23	61.98	134.21	128.43
	(b) Purchase of stock in trade	-	-	-	-	-
	(c) Change in inventories of finished goods & packing Material	(0.89)	(10.25)	(0.02)	(10.27)	(0.81)
	(d) Employee Benefit Expenses	25.18	25.41	25.69	51.10	43.47
	(e) Finance Cost	9.38	6.97	12.39	19.36	19.47
	(f) Depreciation and Amortization Expense	2.87	2.84	2.78	5.62	5.48
	(g) Other Administrative Expenses	39.20	43.02	40.09	83.12	73.60
	Total Expenses	138.94	140.22	142.92	283.14	269.64
3	Profit/(Loss) before Tax (1-2)	1.87	1.04	4.28	5.31	5.12
4	Tax Expenses					
	(a) Current Tax	0.57	0.38	1.24	1.61	1.35
	(b) Deffered Tax	0.32	(0.11)	(0.12)	(0.23)	(0.02)
	(C) Earlier tax	-	-	-	-	-
5	Net Profit / (Loss) for the period (3-4)	1.62	0.77	3.16	3.93	3.79
6	Other Comprehensive Income					
7	Paid - Up equity share capital (Equity Share of Rs. 10/- each)	406.15	406.15	406.150	406.15	406.15
8	Earning per equity share (Rs.)					
	(1) Basic	0.04	0.02	0.08	0.10	0.09
	(2) Diluted	0.04	0.02	0.08	0.10	0.09

Note

- The above results for the half year ended 30-09-2023 have been reviewed by the Audit Committee in their meeting held on 8th Nov 2023 and approved by the Board of Directors in their meeting held on 8th Nov 2023.
- The Financial Results of the company have been prepared in accordance with Accounting Standards (AS) as prescribed under section 133 of the companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014.
- Revenues from Operations is net of trade Discounts/ Trade incentives.
- In accordance with AS 17 on "Operating Segments", the company operated in one business segment viz. Ayurveda Business and hence segment information is not required to be furnished.
- Figures of the corresponding previous period have been regrouped/rearranged wherever necessary to confirm to the classification of the current period.

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director
DIN: 00077026
Place: Virar, Palghar
Date : 8th Nov, 2023



GANGA PHARMACEUTICALS LTD

CIN: L99999MH1989PLC053392

Registered Office: Gangatat, Dhanvantari Marg, Gopcharpada, Virar (East), Palghar -401 305.
Tele Nos.:0250-6098333/444 ; Website: www.ayurvedganga.com; Email id:gangapharmaltd@gmail.com

Statement of Un-Audited Assests and Liabilities as at 30th September, 2023

		Rs.in Lacs	
	Statement of Assets and Liabilities Particulars	As at (30-09-2023)	As at (31-03-2023)
A	EQUITY AND LIABILITIES		
	(1) Shareholders Funds:		
	(a) Share Capital	406.15	406.15
	(b) Reserve & Surplus	140.49	138.86
	(2) Non-Current Liabilities		
	(a) Long-Term Borrowings	72.86	63.46
	(b) Deferred Tax Liabilities (Net)	0.14	0.46
	(c) Other Long Term Liabilities	-	-
	(d) Long Term Provisions	-	-
	(3) Current Liabilities		
	(a) Short-term borrowings	100.48	102.78
	(b) Trade payables		
	i) Total outsatnding dues of micro enterprises and small enterprises	12.49	11.13
	ii) Total outsatnding dues of creditors other then micro enterprises and small enterprises	34.08	46.95
	(c) Other current liabilities	10.88	27.00
	(d) Short-term provisions	2.33	1.61
	Total	779.91	798.41
B	ASSETS		
	(1) Non - Current assets		
	(a) Fixed Assets	62.87	63.94
	(b) Non-current investments	8.50	8.50
	(c) Deferred tax assets (net)	-	-
	(d) Long term loans and advances	-	-
	(e) Other Non-current assets	144.07	211.23
	(2) Current assets		
	(a) Current Investment	-	-
	(b) Inventories	121.54	118.28
	(c) Trade receivables	97.82	88.92
	(d) Cash and cash equivalents	1.99	2.90
	(e) Short-term loans and advances	180.80	143.59
	(f) Other current assets	162.33	161.05
	Total	779.91	798.41

For and on behalf of the Board of Directors
Ganga Pharmaceuticals Limited

Bharat Sharma
Managing Director
DIN : 00077026



Place: Virar, Palghar
Date : 8th Nov, 2023

GANGA PHARMACEUTICALS LIMITED**Cash Flow Statement for the period Ended 30 Septmeber 2023**

(Rs.In lacs)

	For the year ended 30th September 2023 Rupees	For the year ended 30th September 2023 Rupees	For the year ended 31st March 2023 Rupees	For the year ended 31st March 2023 Rupees
A. Cash flow from operating activities:				
Net profit before tax as per Profit and Loss Account.		1.88		5.31
Adjustment to reconcile profit before tax to net cash flows :				
Depreciation and amortisation expense	2.87		5.62	
Interest on advance & deposit recd	(8.88)		(29.82)	
Finance cost	9.38		18.68	
		3.36		(5.52)
Operating profit before working capital changes		5.24		(0.21)
Movements in working capital:				
(Decrease) / Increase in trade payables	(11.51)		5.53	
(Decrease) / Increase in other liabilities	(16.12)		4.37	
(Decrease) / Increase in Short term borrowing	(2.30)		10.77	
(Decrease) / Increase in Short term Provision	0.72		0.26	
(Increase) / Decrease in trade receivables	(8.89)		0.26	
(Increase) / Decrease in other current assets	(1.28)		(35.16)	
(Increase) / Decrease in Short-term loans and advances	(37.20)		15.11	
(Increase) / Decrease in Inventories	(3.27)		(3.28)	
		(79.85)		(2.16)
Cash generated from operations		(74.61)		(2.37)
Taxes paid		(0.57)		(1.61)
Net cash from operating activities		(75.18)		(3.99)
B. Cash flow from investing activities:				
Purchase of fixed assets	(1.79)		(1.48)	
Advances given	-		-	
Deposit made / matured during the year	67.15		20.89	
Investment made during the year	-		-	
Interest received	8.88		29.82	
Net cash used in investing activities		74.24		49.23



Handwritten signature and circular stamp of Ganga Pharmaceuticals Limited. The stamp contains the text "GANGA PHARMACEUTICALS LIMITED" and "GANGA" at the bottom.

GANGA PHARMACEUTICALS LIMITED

(Rs.In lacs)

Cash Flow Statement (Contd.)

	For the year ended 30th September 2023 Rupees	For the year ended 30th September 2023 Rupees	For the year ended 31st March 2022 Rupees	For the year ended 31st March 2022 Rupees
C. Cash flow from financing activities:				
Repayment of borrowings	9.40		(25.71)	
Proceeds from borrowings	-		-	
Finance cost	(9.38)		(18.68)	
Net cash used in financing activities		0.02		(44.39)
Net increase / (Decrease) in cash and cash equivalents		(0.91)		0.86
Cash and cash equivalents as at the beginning of the year		2.90		2.04
Cash and cash equivalents as at the end of the year		1.99		2.90
Cash and cash equivalent comprises of :				
Cash in hand		1.99		2.16
Balance with banks		0.00		0.74
Total		1.99		2.90

Notes:

1. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Notified Accounting Standard - 3 on Cash Flow Statements.
2. Figures in bracket indicate cash outgo.
3. Previous years' figures have been regrouped/rearranged to conform with current years' classifications.

As per our report of even date

For and on behalf of the Board of Directors of
Ganga Pharmaceuticals Limited


Bharat Sharma
Managing Director
DIN : 00077026



Place : Mumbai

Date: 8th Nov 2023